{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Bladder+Carcinoma&page=2", "query": { "condition": "Advanced Bladder Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Bladder+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T06:47:23.722Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumors", "Colorectal Cancer (CRC)", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Renal Cell Carcinoma (RCC)", "Bladder Cancer", "UC (Urothelial Cancer)", "Mesothelioma" ], "interventions": [ { "name": "INCB001158", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2016-09-14", "completion_date": "2022-08-15", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 13, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903914" }, { "nct_id": "NCT00625664", "title": "Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "larotaxel (XRP9881)", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2008-02", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2016-05-05", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 52, "location_summary": "Anchorage, Alaska • Berkeley, California • Burbank, California + 46 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00625664" }, { "nct_id": "NCT01282463", "title": "Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma of Urinary Tract", "Urethral Carcinoma", "Carcinoma of Ureter", "Carcinoma of Renal Pelvis" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Ramucirumab DP", "type": "BIOLOGICAL" }, { "name": "Icrucumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2011-04", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 23 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282463" }, { "nct_id": "NCT04254107", "title": "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Carcinoma", "Gastroesophageal Junction Carcinoma", "Classical Hodgkin Lymphoma", "Diffuse Large B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Cutaneous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Triple Negative Breast Cancer", "Cervical Cancer" ], "interventions": [ { "name": "SEA-TGT", "type": "DRUG" }, { "name": "sasanlimab", "type": "DRUG" }, { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2020-05-29", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04254107" }, { "nct_id": "NCT02632409", "title": "An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Various Advanced Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 709, "start_date": "2016-03-22", "completion_date": "2027-05-27", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 33, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632409" }, { "nct_id": "NCT02807636", "title": "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1213, "start_date": "2016-06-30", "completion_date": "2024-02-12", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 18, "location_summary": "Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02807636" }, { "nct_id": "NCT06910657", "title": "IDOV-Immune for Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer", "Melanoma", "Ovarian Cancer", "Gastric Cancer", "Esophageal Cancer", "Hepatocellular Carcinoma", "Renal Cell Carcinoma", "Breast Cancer", "Sarcoma", "Bladder Cancer", "Lung Cancer", "Prostate Cancer", "Cervical Cancers", "Head and Neck Cancers", "Adrenal Gland Tumors" ], "interventions": [ { "name": "IDOV-Immune (oncolytic vaccinia virus)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ViroMissile, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2025-08-25", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 3, "location_summary": "St Louis, Missouri • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06910657" }, { "nct_id": "NCT00722553", "title": "Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell", "Bladder Cancer", "Bladder Neoplasm" ], "interventions": [ { "name": "Pralatrexate Injection", "type": "DRUG" }, { "name": "Vitamin B12", "type": "DIETARY_SUPPLEMENT" }, { "name": "Folic Acid", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-07", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 4, "location_summary": "Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722553" }, { "nct_id": "NCT05327530", "title": "A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "M6223", "type": "DRUG" }, { "name": "NKTR-255", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2022-08-17", "completion_date": "2026-06-25", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 8, "location_summary": "Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more", "locations": [ { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05327530" }, { "nct_id": "NCT00386516", "title": "Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer of the Bile Duct", "Gallbladder Cancer" ], "interventions": [ { "name": "GM-CT-01", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galectin Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2006-09", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-05-22T06:47:23.722Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00386516" } ] }